In yesterday’s Wall Street session, Vivos Therapeutics Inc (NASDAQ:VVOS) shares traded at $24.50, down -40.24% from the previous session.
As of this writing, 1 analysts cover Vivos Therapeutics Inc (NASDAQ:VVOS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $41.00, this indicates a potential downside of -85.37 percent. VVOS stock price is now 312.70% away from the 50-day moving average and 182.54% away from the 200-day moving average. The market capitalization of the company currently stands at $29.40M.
There are 0 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
In other news, Huntsman Ronald Kirk, Chief Executive Officer bought 14,000 shares of the company’s stock on Jun 20. The stock was bought for $7,420 at an average price of $0.53. Upon completion of the transaction, the Chief Executive Officer now directly owns 86,521 shares in the company, valued at $2.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 16, Chief Executive Officer Huntsman Ronald Kirk bought 15,000 shares of the business’s stock. A total of $8,050 was incurred on buying the stock at an average price of $0.54. This leaves the insider owning 72,521 shares of the company worth $1.78 million. A total of 16.80% of the company’s stock is owned by insiders.
During the past 12 months, Vivos Therapeutics Inc has had a low of $2.73 and a high of $74.05. As of last week, the company has a debt-to-equity ratio of 42.00, a current ratio of 0.28, and a quick ratio of 0.28. The fifty day moving average price for VVOS is $5.94 and a two-hundred day moving average price translates $8.67 for the stock.
The latest earnings results from Vivos Therapeutics Inc (NASDAQ: VVOS) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at -$1.62, beating analysts’ expectations of -$3.12 by 1.5. This compares to -$6.40 EPS in the same period last year. The net profit margin was -106.27% and return on equity was -311.34% for VVOS. The company reported revenue of $3.3 million for the quarter, compared to $4.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -22.26 percent. For the current quarter, analysts expect VVOS to generate $3.6M in revenue.
Vivos Therapeutics Inc(VVOS) Company Profile
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
